Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-06-14

Tempus AI, Inc.

Tempus AI combines molecular diagnostics, clinical workflow software, and de-identified data products to help clinicians and life sciences customers make treatment, research, and drug-development decisions.

ai biotech healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proving the Jump to Precision-Medicine Utility

The upside case is not just more test volume. It is a mix shift toward governed data, workflow, and evidence products that can make each diagnostic interaction more valuable, more recurring, and more defensible.

Analysis

Thesis

Tempus can turn each diagnostic interaction into a compounding data, workflow, and evidence asset; if recent regulatory wins and product launches translate into higher-value recurring revenue, it can grow from a strong precision-oncology tester into a broader precision-medicine operating system with better mix and a higher durable multiple.

Last Economy Alignment

Tempus is not mainly selling human thinking or AI seats; it owns regulated tests, data rights, and workflow surfaces that become more valuable as AI improves. The limiter is that reimbursement and privacy gates can slow conversion of model capability into paid clinical action.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.6x (from 5 most recent analyses)

Reasoning

This is still a revenue-compounding story. The stock works if Tempus keeps growing core oncology diagnostics while proving that data, evidence, and workflow revenue become a larger and stickier share of the mix. I assume some rerating versus traditional diagnostics, but not a pure-software multiple, because reimbursement, privacy, and lab execution will still shape the business in 2031.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is economic conversion, not product existence. Tempus has real products, real demand, and a credible data flywheel, but it still must prove that recent approvals, workflow launches, and biopharma relationships convert into durable, higher-margin revenue before privacy, reimbursement, or incumbent workflow control cap it at a diagnostics-style outcome.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new material filing surfaced in the last 7-10 days; the stock is still digesting the late-May approval and launch cluster.
The key debate has shifted from product readiness to commercial pull-through: investors now need reportable usage, bookings, or mix impact from Preview and refreshed Lens.
No new public disclosure has resolved the core privacy and data-rights overhang, so valuation still depends on governance credibility as much as product breadth.

Thesis update

The core thesis is intact, but one regulatory gate has loosened. The debate is now less about whether Tempus can ship products and more about whether it can turn approvals and launches into visible economic uplift.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.56

They control regulated tests, unique patient data rights, and the workflow screens where cancer decisions get made, so cheaper AI can make their system more useful rather than less. The risk is that privacy rules, reimbursement gates, or hospital software incumbents stop that intelligence from becoming a paid, trusted action layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$66.53

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research